$0.30 0.00 (0.98%) Protalix BioTherapeutics Inc - NYSE Amex Equities

Dec. 9, 2016 | 03:59 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 0.30
Trade Time: Dec 09 03:59 PM Eastern Daylight Time
Change: +0.00 (0.98%)
Prev Close: 0.30
Open: 0.30
Bid: 0.30
Ask: 0.34
  1. No results found.
  1. Insiders Buy Stock in Wynn Resorts, Bank of New York Mellon

    GuruFocus | Oct. 25, 2015 | 20:57PM EST
  2. Protalix BioTherapeutics Reports Positive Long Term Data on PRX-102 for Fabry Disease

    Benzinga | Oct. 19, 2015 | 06:33AM EST
  3. Protalix BioTherapeutics to Explore Non Alcoholic Steato Hepatitis (NASH) as an Indication for Its PRX 106 Oral Anti TNF

    Benzinga | Oct. 5, 2015 | 07:02AM EST
  4. Protalix BioTherapeutics Announces Positive Phase I/II Interim Clinical Data on the 1mg/kg Cohort of PRX-102 for Fabry Disease

    Benzinga | Sep. 9, 2015 | 06:08AM EST
  5. Protalix Reports Phase I Clinical Study Results for PRX-106 Showed Favorable Safety, Tolerability Profile Activity

    Benzinga | Aug. 3, 2015 | 06:34AM EST
  6. Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented at the 38th European Cystic Fibrosis Conference

    Benzinga | Jun. 12, 2015 | 06:30AM EST
  7. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

    Benzinga | Jan. 13, 2015 | 11:34AM EST
  8. Pharmaceuticals, Therapeutics And A Retailer On The Move Thursday Morning

    Benzinga | Jan. 8, 2015 | 09:00AM EST
  9. Avago Technologies' Memory, FBAR, and Connectivity Business Will Take It Higher

    GuruFocus | Oct. 23, 2014 | 10:41AM EST
  10. UPDATE: Protalix Shares Spike Higher on FDA Approval of Pediatric Indication for ELELYSO(TM) for Injection, for IV Use for Treatment of Type 1 Gaucher Disease

    Benzinga | Aug. 28, 2014 | 12:18PM EST
  11. 3 Pharma Companies That Could Deliver Breakthroughs In 'Plantibody' Technology

    Benzinga | Aug. 24, 2014 | 19:08PM EST
  12. Stocks Hitting 52-Week Lows

    Benzinga | Jul. 1, 2014 | 09:20AM EST
  13. Facebook Leads 3 High-Volume Young Gun Stock Leaders

    IBD | Jun. 24, 2014 | 18:14PM EST
  14. Protalix Biotherapeutics Reports New Data on ELELYSO, Oral GCD Will Be Presented at European Working Group on Gaucher Disease

    Benzinga | Jun. 23, 2014 | 06:35AM EST
  15. Protalix Offers Update on Health Canada Evaluation, Says Manufacturing Facility Utilizing ProCellEx Deemed Acceptable by EMA, FDA, IMH, ANVISA, TGA

    Benzinga | Jan. 23, 2014 | 16:35PM EST
Trading Center